Axsome Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-183.2M | $-287.2M | $-239.2M | $-187.1M | $-130.4M | $-102.9M | $-68.3M | $-31.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $503.0K | $532.0K | $459.0K | $263.0K | $76.0K | $23.9K | $37.3K | $48.9K |
| Amortization | $6.4M | $6.4M | $6.4M | $4.1M | — | — | — | — |
| Stock-Based Compensation | $93.8M | $85.2M | $62.6M | $37.7M | $20.8M | $14.8M | $6.1M | $1.8M |
| Net Cash from Operating Activities | $-93.4M | $-128.4M | $-145.1M | $-116.5M | $-108.2M | $-78.5M | $-46.4M | $-30.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $480.0K | $270.0K | $582.0K | $702.0K | $308.0K | $45.9K | $16.1K | $32.7K |
| Business Acquisitions | — | — | — | $53.0M | — | — | — | — |
| Net Cash from Investing Activities | $-480.0K | $-270.0K | $-582.0K | $-53.7M | $-308.0K | $-45.9K | $-16.1K | $-32.7K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $101.5M | $57.8M | $331.0M | $284.6M | $11.1M | $42.4M | $252.4M | $10.0M |
| Net Change in Cash | $7.6M | $-70.8M | $185.4M | $114.4M | $-97.4M | $-36.1M | $206.0M | $-20.1M |
| Free Cash Flow | $-93.9M | $-128.7M | $-145.7M | $-117.2M | $-108.5M | $-78.5M | $-46.4M | $-30.1M |
Behind every stock is a company. Find out what it's doing.